Medera, Novoheart present breakthroughs in human mini-heart platforms, therapy

Medera and Novoheart, its wholly owned pre-clinical subsidiary pioneering human-based cardiac tissue engineering for disease modelling and drug screening, announced the successful presentation of seven scientific abstracts at the 2025 International Society for Stem Cell Research, ISSCR, Annual Meeting, held June 11-14 in Hong Kong. The annual ISSCR meeting brought together nearly 4,000 of the world’s leading stem cell researchers and regenerative medicine experts. Showcased 7 presentations at ISSCR 2025, including a featured oral presentation on first-in-human gene therapy for heart failure, powered by their proprietary human mini-Heart technology. FDA-backed human-based screening platform recognized as an animal-free alternative in drug development, supporting IND and Fast Track approvals under the FDA Modernization Act 2.0. Breakthroughs in high-throughput screening, AI-driven drug classification, and patient-specific disease modelling underscored the platform’s potential to de-risk development and accelerate clinical translation. On September 5, 2024, Medera and Keen Vision Acquisition (KVAC) Corporation announced they had entered into a definitive merger agreement.